Medicenna Therapeutics Announces Key Program Updates and 2026 Outlook

The NEO-CYT study, sponsored by Fondazione Melanoma Onlus, will be evaluating MDNA11 in front-line therapy for resectable ...

Medicenna Therapeutics Corp.: Medicenna Therapeutics Announces Key Program Updates and 2026 Outlook

ORR was 50% in patients treated with MDNA11 in 2L/3L setting and 42% when MDNA11 was the next treatment post-ICI failure, ...

Scottish Rite for Children Receives $2.3M NIH Grant to Advance Bone Regeneration Research in Children With Perthes Disease

Researchers at Scottish Rite for Children received a $2.3 million, five-year grant from the National Institutes of Health (NIH) to study how the body repairs bone and restores blood flow in ...
PharmiWeb

Lantern Pharma Announces Establishing an A.I. Center of Excellence in India to Industrialize the RADR® Platform and Accelerate Global Development Opportunitie…

The A.I. Center of Excellence is planned to be based in Bengaluru and focus on large scale data-engineering, development and ...
PharmiWeb

Molecular Biology for the Non-molecular Biologist Training Course: Elevate Your Expertise in Pharmaceuticals Research, Development and Manufacturing (Apr 20th - Apr 21st, 2026 ...

The "Molecular Biology for the Non-molecular Biologist Training Course (Apr 20th - Apr 21st, 2026)" training has been added to ResearchAndMarkets.com's offering.Elevate your expertise in molecular ...
Le Lézard

Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results

Veracyte, Inc. , a leading cancer diagnostics company, today announced preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025. Preliminary Unaudited ...